Clinical Trials
21 trialsNCT03530683 2024-09-03
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Phase 1 Terminated
NCT03557619 2024-08-29
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
AbbVie
Phase 1 Recruiting
NCT03422393 2024-07-05
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
University of California, San Diego
Phase 1 Active not recruiting
NCT04912063 2024-02-26
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
AbbVie
Phase 1 Terminated
NCT01682616 2023-06-06
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
AbbVie
Phase 1 Completed
NCT03236857 2023-05-22
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
AbbVie
Phase 1 Completed
NCT03484520 2022-12-30
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
AbbVie
Phase 1 Terminated
NCT03082209 2022-12-09
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
AbbVie
Phase 1 Completed
NCT03000257 2022-04-14
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT01328626 2022-02-23
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
AbbVie
Phase 1 Completed
NCT03441555 2022-02-01
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
AbbVie
Phase 1 Completed
NCT03797261 2021-12-07
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
AbbVie
Phase 1 Terminated
NCT03181126 2021-10-14
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
AbbVie
Phase 1 Completed
NCT03625505 2021-09-14
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
AbbVie
Phase 1 Completed
NCT01594229 2021-08-02
A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
AbbVie
Phase 1 Completed
NCT04274907 2021-02-11
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
AbbVie
Phase 1 Terminated
NCT04274933 2020-10-29
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
AbbVie
Phase 1 Terminated
NCT01969695 2019-12-19
An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma
AbbVie
Phase 1 Completed
NCT02391480 2019-11-29
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
AbbVie
Phase 1 Completed
NCT01969669 2017-11-20
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199
AbbVie
Phase 1 Completed
NCT01969682 2014-05-26
A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199
AbbVie
Phase 1 Withdrawn